Back to brief archive
Agentic Daily · Friday, May 1, 2026Healthcare

J&J drops two CAR-T programs as cell therapy market shifts

Pharma giant cites competitive landscape changes in B-cell lymphoma treatment space.

Today, in 3
01
MARKETEndpoints NewsVerified
J&J discontinues two CAR-T lymphoma programs citing market evolution
Summary

Johnson & Johnson terminated two CAR-T cell therapy programs targeting B-cell lymphoma. The company cited recent approvals of competing cell therapies and antibody-based drugs in the lymphoma treatment space.

Our take

Major pharma pulling back from CAR-T suggests the manufacturing complexity and cost structure can't compete with newer antibody approaches. Single source — verify before acting.

What this means for practitioners

R&D portfolio managers should audit their own cell therapy investments against antibody-drug conjugate timelines. Finance teams should model the competitive risk to any CAR-T programs in late-stage development.

02
RESEARCHEndpoints NewsVerified
Summit stock drops 20% on ivonescimab Phase 3 statistical miss
Summary

Summit Therapeutics shares fell nearly 20% after hours following an apparent statistical miss in part of a Phase 3 trial for cancer drug ivonescimab. The interim analysis did not meet the statistical threshold for the planned endpoint.

Our take

Interim futility analyses are designed to stop trials early when success is unlikely, saving costs but crushing valuations. Market reaction suggests investors expected stronger interim signals from this PD-1 inhibitor program.

What this means for practitioners

Clinical operations teams should review their own interim analysis triggers and statistical powering assumptions. Investor relations should prepare for similar volatility if your trials have interim readouts scheduled.

03
DEALBioPharma DiveVerified
Seaport and Hemab price IPOs raising combined $556M
Summary

Seaport Therapeutics and Hemab Therapeutics completed IPOs raising a combined $556 million on Thursday. The offerings continue a strong 2026 biotech IPO market that has raised almost $3.2 billion year-to-date.

Our take

Public market appetite for biotech remains strong despite recent trial failures elsewhere. Window may close if more high-profile interim analyses disappoint investors.

What this means for practitioners

CFOs with IPO plans should accelerate timeline discussions with underwriters while market conditions remain favorable. Business development teams should expect higher private valuations as public comps strengthen.

Stat of the Day
Biotech IPO proceeds YTD
$3.2B
Total raised by biotech companies going public in 2026 through April (per BioPharma Dive).
Source: BioPharma Dive
1 Insight
Biotech markets are showing clear winners and losers based on clinical execution. Strong IPO appetite coexists with brutal punishment for trial misses, creating a bifurcated funding environment where success and failure get amplified.
1 Action
Portfolio managers: stress-test your Phase 3 statistical assumptions against Summit's miss before next board meeting so you can adjust interim analysis triggers.
Watch this week
Themes
  • ·Clinical trial risk pricing
  • ·CAR-T competitive pressure
Opportunities
  • +IPO window remains open for well-positioned biotechs
  • +Antibody-drug conjugates gaining ground vs cell therapies
Risks
  • !Interim analysis volatility increasing investor sensitivity
  • !CAR-T manufacturing costs pressuring program viability
Read this edition for your role

Persona editions

GeneralConsultantFinanceHealthcareLegalHRDeveloperFounderGTM